• APJ is mainly coupled to PTX

  2024-01-29

  

  APJ is mainly coupled to PTX-sensitive Gi/o proteins [33], and thus, it is associated with the inhibition of adenylyl cyclase and the activations of PI3K/Akt signaling and MAPKs signaling pathways [23], [54], [55], [56]. In a previous study, apelin stimulations of the PI3K/Akt and/or the MAPK pathwa

• Recent studies have supported the existence of

  2024-01-29

  

  Recent studies have supported the existence of an inward RAS regulatory mechanism in which AT1 receptors downregulate angiotensin-converting enzyme 2 (ACE2) and subsequently impair angiotensin-(1-7) generation and MAS functionality (Jessup et al., 2006, Gallagher et al., 2008, Xia et al., 2009, Pern

• We provide here direct evidences that AT

  2024-01-29

  

  We provide here direct evidences that AT1 receptors are active in ADSCs since Ang II induces intracellular Ca mobilization in these cells. Data obtained during the observation of Ca influxes led us to the search for the ADSCs subpopulation constantly expressing AT1 receptor. ADSCs are necessary for

• Rivaroxaban receptor PF is orally bioavailable and has appro

  2024-01-29

  

  PF-06409577 is orally bioavailable and has appropriate pharmacokinetic properties for use in rodents, allowing us to evaluate its impact on lipid and cholesterol biosynthesis in vivo (Cameron et al., 2016). PF-06409577 lowered the incorporation of 14C-acetate into hepatic lipids in vivo in a dose de

• br Acknowledgements This work was supported

  2024-01-29

  

  Acknowledgements This work was supported by Programme Grants from the MRC and the Wellcome Trust (SGC-C and MF). CB was in receipt of a Marie Curie Intra-European Fellowship during part of this work. We thank past and present members of our group for numerous valuable discussions throughout these

• Ellagic acid receptor At the organismal level skeletal muscl

  2024-01-27

  

  At the organismal level, skeletal muscle, lung and adipose tissues mediate net de novo synthesis and release of glutamine, whereas net glutamine catabolism occurs in the kidney [7]. The liver exhibits net glutamine consumption coupled to urea production in the post-absorptive state, and net glutamin

• To our knowledge BAY has not progressed

  2024-01-27

  

  To our knowledge, BAY 60-6583 has not progressed to clinical development and remains to be the only ADORA2B agonist that has been developed.33, 34 Further development of similar compounds would be beneficial in future fibrosis research. One of the limitations of our study is being limited to in vit

• Despite these efforts to prevent oxidative metabolic degrada

  2024-01-27

  

  Despite these efforts to prevent oxidative metabolic degradation, and showed only marginal improvements in metabolic stability and still exhibited high plasma clearances as shown in . High molecular weight as well as relative high log values could be contributing factors to the poor PK profiles of a

• br Materials and methods br Results

  2024-01-27

  

  Materials and methods Results Discussion Cdc42 has been implicated in mediating the entry of HCV into hepatocytes, but how Cdc42 affects the response of HCV patients to IFN therapy is unknown. This study therefore examined the genetic association between Cdc42-related genes and efficacy of

• The srd a isoforms showed unique expression

  2024-01-27

  

  The srd5a isoforms showed unique expression profiles in early FHM development (Fig. 2). Similar to amphibian embryos, there was a high abundance of both srd5a1 and srd5a3 at 1dpf in FHMs, suggesting that mRNA for these enzymes may be maternally deposited and that these enzymes may play a key role in

• Two parallel branches of the DNA damage

  2024-01-27

  

  Two parallel branches of the DNA damage-dependent S-phase checkpoint are thought to co-operate by inhibiting distinct steps of DNA replication. One branch includes the phosphorylation of structural maintenance of chromosomes 1 (SMC1), a cohesin that is activated by ATM or ATR after IR treatment or r

• br Introduction Hepatocellular carcinoma HCC is

  2024-01-26

  

  Introduction Hepatocellular carcinoma (HCC) is an aggressive and malignant cancer detected in clinical practice, as it is the third key reason of tumor-related deaths worldwide, with > 800, 000 mortalities every year (Torre et al., 2015). Current treatments for HCC are surgical therapy, liver tra

• VEGFR inhibition using sunitinib does not result

  2024-01-26

  

  VEGFR2 inhibition using sunitinib does not result in tumor growth reduction or in a further decrease in vessel density in NDRG1 overexpressing glioma rendering these tumors intrinsically resistant to antiangiogenic treatment. Intrinsic resistance to antiangiogenic therapy is defined as a non-respons

• Furthermore a recently published network

  2024-01-26

  

  Furthermore, a recently published network meta-analysis including 30 trials in patients with hypertension and diabetes demonstrated that ARBs have efficacy similar to that of ACEIs for all-cause and cardiovascular mortality (HR 0.95, 95% CI 0.73 to 1.30 and HR 1.23, 95% CI 0.64 to 2.78, respectivel

• The current results also demonstrated

  2024-01-26

  

  The current results also demonstrated tendencies toward decreased serum Aβ40 levels and increased Aβ42 levels during the 1-year follow-up. These tendencies are consistent with the results of a previous study that evaluated Aβs in the CSF of patients with late-life depression (Pomara et al., 2016). T

15546 records 206/1037 page Previous Next First page 上5页 206207208209210 下5页 Last page